



## Rhythm Pharmaceuticals to Present at Cowen & Co. 40th Annual Health Care Conference

February 25, 2020

BOSTON, Feb. 25, 2020 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a late-stage biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic disorders of obesity, today announced that Murray Stewart, M.D., Chief Medical Officer of Rhythm, and Hunter Smith, Chief Financial Officer of Rhythm, will participate in a fireside chat at the Cowen & Co. 40<sup>th</sup> Annual Health Care Conference on Tuesday, March 3, 2020 at 8:00 a.m. ET in Boston, MA.

A live audio webcast of the presentation will be available under "Events & Presentations" in the Investor Relations section of the Company's website at [www.rhythmtx.com](http://www.rhythmtx.com). A replay of the webcast will be available on the Rhythm website for 30 days following each presentation.

### About Rhythm

Rhythm is a biopharmaceutical company focused on the development and commercialization of therapies for the treatment of rare genetic disorders of obesity. The company recently announced positive topline results from pivotal Phase 3 clinical trials of setmelanotide, its MC4R agonist, in people living with POMC deficiency obesity and LEPR deficiency obesity, and plans to complete its first rolling NDA submission to the FDA in the first quarter of 2020. Rhythm is also evaluating setmelanotide in a pivotal Phase 3 trial in people living with Bardet-Biedl and Alström syndromes, with topline data from this trial expected in the fourth quarter of 2020 or early in the first quarter of 2021. Rhythm is leveraging the Rhythm Engine -- comprised of its Phase 2 basket study, TEMPO Registry, GO-ID genotyping study and Uncovering Rare Obesity program -- to improve the understanding, diagnosis and potentially the treatment of rare genetic disorders of obesity. For healthcare professionals, visit [www.UNcommonObesity.com](http://www.UNcommonObesity.com) for more information. For patients and caregivers, visit [www.LEADforRareObesity.com](http://www.LEADforRareObesity.com) for more information. The company is based in Boston, MA.

### Corporate Contact:

David Connolly  
Head of Investor Relations and Corporate Communications  
Rhythm Pharmaceuticals, Inc.  
857-264-4280  
[dconnolly@rhythmtx.com](mailto:dconnolly@rhythmtx.com)

### Investor Contact:

Hannah Deresiewicz  
Stern Investor Relations, Inc.  
212-362-1200  
[hannah.deresiewicz@sternir.com](mailto:hannah.deresiewicz@sternir.com)

### Media Contact:

Adam Daley  
Berry & Company Public Relations  
212-253-8881  
[adaley@berrypr.com](mailto:adaley@berrypr.com)



Source: Rhythm Pharmaceuticals, Inc.